ShadiSadat Seyyedebrahimi1, Hadi Khodabandehloo1, Ensieh Nasli Esfahani2,3, Reza Meshkani4,5,6. 1. Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. 2. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. 4. Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. rmeshkani@tums.ac.ir. 5. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. rmeshkani@tums.ac.ir. 6. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. rmeshkani@tums.ac.ir.
Abstract
AIMS: Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have shown that resveratrol exerts an antioxidant effect, but clinical trials addressing this effect in patients with T2D are limited. The aim of this study was to determine whether resveratrol supplementation affects oxidative stress markers in a randomized, placebo-controlled, double-blind clinical trial. METHODS: A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months. Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular superoxide anion (O2-·) and hydrogen peroxide (H2O2) in PBMCs, the expression of genes involved in oxidative stress responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured at the baseline and at the trial end. RESULTS: Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O2-· level and significantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and SOD was significantly increased after resveratrol consumption. Resveratrol had no significant effects on the metabolic and anthropometric parameters except for a significant reduction in weight, BMI, and blood pressure levels. Resveratrol was well tolerated, and no serious adverse event was occurred. CONCLUSIONS: Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D. Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752 .
RCT Entities:
AIMS: Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have shown that resveratrol exerts an antioxidant effect, but clinical trials addressing this effect in patients with T2D are limited. The aim of this study was to determine whether resveratrol supplementation affects oxidative stress markers in a randomized, placebo-controlled, double-blind clinical trial. METHODS: A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months. Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular superoxide anion (O2-·) and hydrogen peroxide (H2O2) in PBMCs, the expression of genes involved in oxidative stress responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured at the baseline and at the trial end. RESULTS: Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O2-· level and significantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and SOD was significantly increased after resveratrol consumption. Resveratrol had no significant effects on the metabolic and anthropometric parameters except for a significant reduction in weight, BMI, and blood pressure levels. Resveratrol was well tolerated, and no serious adverse event was occurred. CONCLUSIONS: Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D. Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752 .
Authors: Carolina Simioni; Giorgio Zauli; Alberto M Martelli; Marco Vitale; Gianni Sacchetti; Arianna Gonelli; Luca M Neri Journal: Oncotarget Date: 2018-03-30
Authors: Arthur José Pontes Oliveira de Almeida; Mathania Silva de Almeida Rezende; Sabine Helena Dantas; Sonaly de Lima Silva; Júlio César Pinheiro Lúcio de Oliveira; Fátima de Lourdes Assunção Araújo de Azevedo; Rayanne Maira Felix Ribeiro Alves; Geovânia Maria Sales de Menezes; Pablo Ferreira Dos Santos; Tays Amanda Felisberto Gonçalves; Valérie B Schini-Kerth; Isac Almeida de Medeiros Journal: Oxid Med Cell Longev Date: 2020-05-08 Impact factor: 6.543
Authors: Maya M Jeyaraman; Nameer S H Al-Yousif; Amrinder Singh Mann; Vernon W Dolinsky; Rasheda Rabbani; Ryan Zarychanski; Ahmed M Abou-Setta Journal: Cochrane Database Syst Rev Date: 2020-01-17